Rare skin adverse reactions induced by osimertinib: a case report and literature review
Osimertinib is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) used in the treatment of EGFR mutation-positive advanced non-small cell lung cancer. Osimertinib-induced cutaneous vasculitis is a rare skin adverse reaction. We present a case study of a 49-year-...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1523541/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832591041652326400 |
|---|---|
| author | Ye Zhang Mingzhu Ling Min Wang Ye Chen Liting Zhang |
| author_facet | Ye Zhang Mingzhu Ling Min Wang Ye Chen Liting Zhang |
| author_sort | Ye Zhang |
| collection | DOAJ |
| description | Osimertinib is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) used in the treatment of EGFR mutation-positive advanced non-small cell lung cancer. Osimertinib-induced cutaneous vasculitis is a rare skin adverse reaction. We present a case study of a 49-year-old female who developed palpable purpura on her lower extremities on the 11th day of osimertinib treatment. Systemic involvement was not observed in the test results. The multidisciplinary team considered the clinical presentation of purpura as a potential case of cutaneous vasculitis. Osimertinib was immediately discontinued, and intravenous methylprednisolone along with oral cetirizine treatment was initiated. After 8 days since discontinuation of osimertinib, the patient’s skin purpura completely subsided. Subsequently, she was switched to almonertinib for treatment. We also conducted a literature review cutaneous vasculitis induced by osimertinib and other EGFR-TKIs. We hope to provide some safety alert information for clinical practice and recommend enhanced monitoring during the medication process. |
| format | Article |
| id | doaj-art-86d06164661d4fdebc9e0e490a6a0dfd |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-86d06164661d4fdebc9e0e490a6a0dfd2025-01-23T05:10:24ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-01-011510.3389/fonc.2025.15235411523541Rare skin adverse reactions induced by osimertinib: a case report and literature reviewYe Zhang0Mingzhu Ling1Min Wang2Ye Chen3Liting Zhang4Department of Pharmacy, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, ChinaDepartment of Pulmonary and Critical Care Medicine, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, ChinaDepartment of Pharmacy, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, ChinaDepartment of Pulmonary and Critical Care Medicine, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, ChinaDepartment of Pulmonary and Critical Care Medicine, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, ChinaOsimertinib is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) used in the treatment of EGFR mutation-positive advanced non-small cell lung cancer. Osimertinib-induced cutaneous vasculitis is a rare skin adverse reaction. We present a case study of a 49-year-old female who developed palpable purpura on her lower extremities on the 11th day of osimertinib treatment. Systemic involvement was not observed in the test results. The multidisciplinary team considered the clinical presentation of purpura as a potential case of cutaneous vasculitis. Osimertinib was immediately discontinued, and intravenous methylprednisolone along with oral cetirizine treatment was initiated. After 8 days since discontinuation of osimertinib, the patient’s skin purpura completely subsided. Subsequently, she was switched to almonertinib for treatment. We also conducted a literature review cutaneous vasculitis induced by osimertinib and other EGFR-TKIs. We hope to provide some safety alert information for clinical practice and recommend enhanced monitoring during the medication process.https://www.frontiersin.org/articles/10.3389/fonc.2025.1523541/fulladverse drug reactioncutaneous vasculitisosimertinibEGFR-TKIscase report |
| spellingShingle | Ye Zhang Mingzhu Ling Min Wang Ye Chen Liting Zhang Rare skin adverse reactions induced by osimertinib: a case report and literature review Frontiers in Oncology adverse drug reaction cutaneous vasculitis osimertinib EGFR-TKIs case report |
| title | Rare skin adverse reactions induced by osimertinib: a case report and literature review |
| title_full | Rare skin adverse reactions induced by osimertinib: a case report and literature review |
| title_fullStr | Rare skin adverse reactions induced by osimertinib: a case report and literature review |
| title_full_unstemmed | Rare skin adverse reactions induced by osimertinib: a case report and literature review |
| title_short | Rare skin adverse reactions induced by osimertinib: a case report and literature review |
| title_sort | rare skin adverse reactions induced by osimertinib a case report and literature review |
| topic | adverse drug reaction cutaneous vasculitis osimertinib EGFR-TKIs case report |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1523541/full |
| work_keys_str_mv | AT yezhang rareskinadversereactionsinducedbyosimertinibacasereportandliteraturereview AT mingzhuling rareskinadversereactionsinducedbyosimertinibacasereportandliteraturereview AT minwang rareskinadversereactionsinducedbyosimertinibacasereportandliteraturereview AT yechen rareskinadversereactionsinducedbyosimertinibacasereportandliteraturereview AT litingzhang rareskinadversereactionsinducedbyosimertinibacasereportandliteraturereview |